Search Result
Results for "
bone formation
" in MedChemExpress (MCE) Product Catalog:
1
Biochemical Assay Reagents
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-B2200
-
|
Tricalcium dicitrate tetrahydrate, 99%
|
Calcium Channel
Biochemical Assay Reagents
|
Metabolic Disease
|
|
Calcium citrate tetrahydrate, 99% exhibits the ability to release more calcium ions in a short time therefore allowing a high activity, and a high concentration of calcium ions that can stimulate bone formation .
|
-
-
- HY-15100
-
|
AAE581
|
Cathepsin
|
Inflammation/Immunology
|
|
Balicatib (AAE581) is a potent, orally active and selective cathepsin K inhibitor with IC50 values of 22, 61, 48, 2900 nM for cathepsin K, cathepsin B, cathepsin L, cathepsin S, respectively. Balicatib inhibits bone turnover, decreases bone formation rates. Balicatib has the potential for the research of osteoporosis .
|
-
-
- HY-108624
-
-
-
- HY-P0322
-
|
EMD 56574
|
Integrin
|
Cardiovascular Disease
Metabolic Disease
|
|
GRGDSPK (EMD 56574) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK (EMD 56574) is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK is used to study the role of integrins in bone formation and resorption .
|
-
-
- HY-148043
-
|
|
Others
|
Others
|
|
Schnurri-3 inhibitor-1 is a potent schnurri-3 inhibitor which is an essential regulator of adult bone formation. Schnurri-3 inhibitor-1 can inhibit Shn3 with EF1alpha promoter in osteoblast cell line Shn3FFL with an AC50 value of 2.09 μM. Schnurri-3 inhibitor-1 can be used to research osteoporosis .
|
-
-
- HY-127090
-
|
MDP
|
p38 MAPK
NOD-like Receptor (NLR)
|
Inflammation/Immunology
Cancer
|
|
Muramyl dipeptide (MDP) is a synthetic immunoreactive peptide, consisting of N-acetyl muramic acid attached to a short amino acid chain of L-Ala-D-isoGln. Muramyl dipeptide is an inducer of bone formation through induction of Runx2. Muramyl dipeptide directly enhances osteoblast differentiation by up-regulating Runx2 gene expression through MAPK pathways. Muramyl dipeptide is a NLRP1 agonist .
|
-
-
- HY-P5929
-
|
|
Integrin
FAK
|
Inflammation/Immunology
|
|
VnP-16 can promote bone formation by accelerating osteoblast differentiation and activity through direct interaction with β1 integrin followed by FAK activation .
|
-
-
- HY-P0322A
-
|
EMD 56574 TFA
|
Integrin
|
Cardiovascular Disease
Metabolic Disease
|
|
GRGDSPK TFA (EMD 56574 TFA) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK TFA is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK TFA is used to study the role of integrins in bone formation and resorption .
|
-
-
- HY-150186
-
|
|
RXFP Receptor
|
Metabolic Disease
|
|
RXFP2 agonist 2 is a selective，orally active and allosteric RXFP2 agonist with an EC50 value of 0.38 µM. RXFP2 agonist 2 induces osteoblast mineralization. RXFP2 agonist 2 increases bone formation in female mice. RXFP2 agonist 2 has the potential for the research of osteoporosis .
|
-
-
- HY-116198
-
|
|
15-PGDH
|
Metabolic Disease
|
|
15-PGDH-IN-2 (Compound 2) is a 15-PGDH inhibitor with an IC50 value of 0.274 nM. 15-PGDH-IN-2 can be used in research on hair loss, bone formation, gastric ulcer healing, and dermal wound healing .
|
-
-
- HY-128431
-
|
|
Reactive Oxygen Species
|
Neurological Disease
Metabolic Disease
|
|
Arochlor 1254 is a polychlorinated biphenyl (PCB) mixture with biphenyl and 54% chlorine. Aroclor 1254 reduced cell viability and induced overproduction of intracellular reactive oxygen species in a dose-dependent manner. Arochlor 1254 exposure reduces calcium homeostasis, osteoblast differentiation and bone formation .
|
-
-
- HY-15147
-
XAV-939
Maximum Cited Publications
128 Publications Verification
|
β-catenin
PARP
|
Cancer
|
|
XAV-939 is a Tankyrase inhibitor. XAV-939 has inhibitory activity for TNKS1 and TNKS2 with IC50 values of 5 nM and 2 nM, respectively. XAV-939 also is an enhancer of osteoblastic differentiation of hMSCs. XAV-939 can be used for the research of conditions associated with activated Wnt signaling, such as cancer, fibrotic diseases and conditions associated with low bone formation .
|
-
-
- HY-N7702
-
|
|
Wnt
β-catenin
|
Metabolic Disease
|
|
N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide is a macamide isolated from Maca (Lepidium meyenii Walp.) N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide induces mesenchymal stem cells osteogenic differentiation and consequent bone formation through activating the canonical Wnt/β‐catenin signaling pathway. N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide can be used for the research of osteoporosis .
|
-
-
- HY-P0090
-
|
Salmon calcitonin
|
CGRP Receptor
|
Cancer
|
|
Calcitonin salmon, a calcium regulating hormone, is a dual-action amylin and calcitonin receptor agonist, could stimulate bone formation and inhibit bone resorption.
|
-
-
- HY-P0090A
-
|
Salmon calcitonin acetate
|
CGRP Receptor
|
Cancer
|
|
Calcitonin (salmon) (acetate) is a dual-action amylin and calcitonin receptor agonist, can stimulate bone formation and inhibit bone resorption .The acetate form can affect the absorption and efficacy of hormones .
|
-
-
- HY-14839A
-
-
-
- HY-N10117
-
|
|
RANKL/RANK
|
Others
|
|
2,3-Bis(3-indolylmethyl)indole significantly suppresses RANKL-induced osteoclast formation, actin ring formation, and bone resorption in a concentration-dependent manner.
|
-
-
- HY-14839
-
-
-
- HY-148698
-
|
|
VD/VDR
|
Others
|
|
2MD is an orally active vitamin D analog. 2MD stimulates periosteal bone formation and decreases trabecular bone resorption. Thus 2MD restores trabecular and cortical bone mass and strength. 2MD also regulates intraocular pressure (IOP)-relative genes and reduces IOP in non-human primates .
|
-
-
- HY-N2403
-
|
|
Others
|
Neurological Disease
|
|
Dihydrolycorine, isolated from Lycoris radiate Herb, is an inhibitor of protein synthesis in eukarytic cells by inhibiting the peptide bone formation step .
|
-
-
- HY-167679
-
|
|
Others
|
Inflammation/Immunology
|
|
Scio-323 is an orally available p38 mitogen-activated protein kinase (MAPK) inhibitor with the potential to inhibit chronic inflammatory responses associated with polyethylene particles. Scio-323's oral inhibition pattern had a minimal effect on bone formation. Scio-323 administration inhibited net bone formation after the establishment of a chronic inflammatory response to polyethylene particles. Osteoblast-like activity remained low in all cases of Scio-323 inhibition. Scio-323 failed to improve bone growth in the presence of polyethylene particles .
|
-
-
- HY-17397
-
|
Distrontium renelate; S12911
|
CaSR
|
Metabolic Disease
|
|
Strontium Ranelate (S12911) is an antiosteoporotic agent that acts by reducing bone resorption and promoting bone formation, thereby inducing a positive bone balance. Strontium Ranelate can also activate the calcium-sensing receptor (CaSR) in non skeletal cells, resulting in the activation of inositol 1, 4, 5-triphosphate production and mitogen-activated protein kinase signaling .
|
-
-
- HY-118668
-
|
|
Others
|
Others
|
|
ABD-350 is an antiresorptive agent that inhibits osteoclast activity without affecting osteoblast activity and preventing ovariectomy-induced bone loss. ABD-350 inhibits NF-κB ligand-induced inhibitor of NF-κB phosphorylation, leading to osteoclast apoptosis, but has no inhibitory effect on osteoblast function, effectively preventing bone loss in ovariectomized mice, and does not inhibit parathyroid hormone-induced bone formation.
|
-
-
- HY-N7646
-
|
|
Others
|
Others
|
|
Curculigoside B, a phenolic glycoside isolated from Curculigo orchioides, enhances the osteoblast proliferation, decreases the area of bone resorption pit, osteoclastic formation and TRAP activity. Antiosteoporotic and antioxidative activities .
|
-
-
- HY-17397R
-
|
|
CaSR
|
Metabolic Disease
|
|
Strontium Ranelate (Standard) is the analytical standard of Strontium Ranelate. This product is intended for research and analytical applications. Strontium Ranelate (S12911) is an antiosteoporotic agent that acts by reducing bone resorption and promoting bone formation, thereby inducing a positive bone balance. Strontium Ranelate can also activate the calcium-sensing receptor (CaSR) in non skeletal cells, resulting in the activation of inositol 1, 4, 5-triphosphate production and mitogen-activated protein kinase signaling .
|
-
-
- HY-162866
-
|
|
Autophagy
|
Metabolic Disease
|
CXM102 is an autophagy activator. CXM102 can induce autophagy in aged BMSCs, leading to the rejuvenation of BMSCs and preferential differentiation into osteoblasts. CXM102 promotes the nuclear translocation of transcription factor EB (TFEB) and the formation of osteoblasts. CXM102 can stimulate bone synthesis metabolism in middle-aged male mice, reduce bone marrow adipocytes, delay bone loss, lower serum inflammation levels, decrease organ fibrosis, and extend the lifespan of the mice .
|
-
-
- HY-P4823
-
|
|
Thyroid Hormone Receptor
|
Metabolic Disease
|
|
pTH (1-37) (human) is a fragment of parathyroid hormone (PTH). pTH (1-37) (human) induces the cAMP formation and increases alkaline phosphatase activity. pTH (1-37) (human) increases growth, bone calcium content, and bone mineral density (BMD) in uremic animals. pTH (1-37) (human) has the potential for the research of osteoporosis .
|
-
-
- HY-11035
-
|
|
β-catenin
|
Cancer
|
|
WAY-262611 is a wingless β-Catenin agonist that increases bone formation rate with an EC50 of 0.63 μM in TCF-Luciferase assay. WAY-262611 is also a Dkk1 inhibitor.
|
-
-
- HY-158203
-
|
|
Others
|
Others
|
|
BMP agonist 2 (derivative I-9) is a potent bone-inducing cytokine. BMP agonist 2 promotes bone tissue production by increasing the proportion and activity of osteoblasts. BMP agonist 2 promotes osteoblast proliferation and differentiation through the BMP2-ATF4 signaling axis, in which ATF4 is a transcription factor closely related to osteoblast differentiation and bone formation. BMP agonist 2 can be used in the study of senile osteoporosis (SOP) .
|
-
-
- HY-B1246
-
|
|
Bacterial
Proton Pump
|
Infection
|
|
Thonzonium bromide is an antibacterial agent that is structurally similar to Farnesol (HY-Y0248A). Thonzonium bromide is also a monocationic surface-active agent, which inhibits RANKL-induced osteoclast formation and bone resorption in vitro and prevents LPS-induced bone loss in vivo. Thonzonium bromide inhibits proton transport in a dose-dependent manner (EC50=69 μM) .
|
-
-
- HY-N4299
-
|
|
Others
|
Metabolic Disease
|
|
Caesappanin C, a biphenyl dimer from the ethanolic extract of the heartwood of Indonesian Caesalpinia sappan L., shows strong proliferation stimulating activity against the primary osteoblastic cells in vitro. Caesappanin C has the potential to stimulate bone formation and regeneration .
|
-
-
- HY-P4817
-
|
|
Thyroid Hormone Receptor
|
Metabolic Disease
|
|
Human PTH-(1-31) is the 1-31 fragment of human PTH. Human PTH-(1-31) stimulates the release of cAMP and also is a weaker stimulator of the 25-hydroxyvitamin D-1α-hydroxylase. Human PTH-(1-31) induces bone formation without inducing bone resorption. Human PTH-(1-31) has the potential for the research of osteoporosis .
|
-
-
- HY-112499
-
|
Vitamin K2-7; Vitamin K2(35); Vitamin MK-7
|
Others
|
Cardiovascular Disease
|
|
Menaquinone-7 (Vitamin K2-7), belongs to a class of K2-vitamin homologs (orally active), is originally discovered as the anti-hemorrhagic factors. Menaquinone-7 inhibits osteoclast bone resorption in vitro and stimulates bone formation in femoral tissue of aged female rats. Menaquinone-7 has a well-researched potential in the prevention of aging-induced bone degeneration. Menaquinone-7 is also a pharmacological option for activating Gla matrix protein and intervening in the progression of calcific aortic stenosis (CAVS) .
|
-
-
- HY-111162
-
|
|
GPR55
GlyT
|
Cardiovascular Disease
Neurological Disease
|
|
GSK494581A is a specific ligand for human GPR55 (pEC50 of 6.8) and also acts as an inhibitor of glycine transporter subtype 1 (GlyT1). GSK494581A may regulate pain signaling, bone morphogenesis, and vascular endothelial cell formation by binding to GPR55 .
|
-
-
- HY-B1246R
-
|
|
Bacterial
Proton Pump
|
Infection
|
|
Thonzonium (bromide) (Standard) is the analytical standard of Thonzonium (bromide). This product is intended for research and analytical applications. Thonzonium bromide is an antibacterial agent that is structurally similar to Farnesol (HY-Y0248A). Thonzonium bromide is also a monocationic surface-active agent, which inhibits RANKL-induced osteoclast formation and bone resorption in vitro and prevents LPS-induced bone loss in vivo. Thonzonium bromide inhibits proton transport in a dose-dependent manner (EC50=69 μM) .
|
-
-
- HY-149852
-
|
|
Others
|
Inflammation/Immunology
|
|
Anti-osteoporosis agent-3 (Compound 11), a PMSA derivative, is an anti-osteoporosis agent. Anti-osteoporosis agent-3 inhibits osteoclastogenesis with an IC50 value of 322.9 nM in vitro. Anti-osteoporosis agent-3 also blocks the formation of F-action belts and bone resorption .
|
-
-
- HY-112499R
-
|
Vitamin K2-7(Standard); Vitamin K2(35)(Standard); Vitamin MK-7 (Standard)
|
Others
|
Cardiovascular Disease
|
|
Menaquinone-7 (Standard) is the analytical standard of Menaquinone-7. This product is intended for research and analytical applications. Menaquinone-7 (Vitamin K2-7), belongs to a class of K2-vitamin homologs (orally active), is originally discovered as the anti-hemorrhagic factors. Menaquinone-7 inhibits osteoclast bone resorption in vitro and stimulates bone formation in femoral tissue of aged female rats. Menaquinone-7 has a well-researched potential in the prevention of aging-induced bone degeneration. Menaquinone-7 is also a pharmacological option for activating Gla matrix protein and intervening in the progression of calcific aortic stenosis (CAVS) .
|
-
-
- HY-15106
-
|
|
CaSR
|
Metabolic Disease
Inflammation/Immunology
|
|
SB-423557 is an orally active calcium-sensing receptor (CaR) antagonist (IC50=520 nM), precursor of SB-423562 (IC50=73 nM). SB-423557 is well tolerated in human and increases plasma concentrations of exogenous parathyroid hormone (PTH) and stimulates bone formation .
|
-
-
- HY-108742
-
|
BA 058; BIM 44058
|
Thyroid Hormone Receptor
Arrestin
|
Metabolic Disease
|
|
Abaloparatide (BA 058) is a parathyroid hormone receptor 1 (PTHR1) analog. Abaloparatide also is a selective PTHR1 activator. Abaloparatide enhances Gs/cAMP signaling and β-arrestin recruitment. Abaloparatide enhances bone formation and cortical structure in mice. Abaloparatide has the potential for the research of osteoporosis .
|
-
-
- HY-161869
-
|
|
Histone Methyltransferase
|
Metabolic Disease
|
|
LSD1-IN-32 (compound 11e) is a potent LSD1 inhibitor with an IC50 value of 0.99 µM. LSD1-IN-32 inhibits RANKL-induced osteoclastogenesis, bone resorption and F-actin belt formation. LSD1-IN-32 has the potential for the research of osteoporosis .
|
-
-
- HY-108742A
-
|
BA 058 TFA; BIM 44058 TFA
|
Thyroid Hormone Receptor
Arrestin
|
Metabolic Disease
Endocrinology
|
|
Abaloparatide TFA (BA 058 TFA) is a parathyroid hormone receptor 1 (PTHR1) analogue. Abaloparatide TFA also is a selective PTHR1 activator. Abaloparatide TFA enhances Gs/cAMP signaling and β-arrestin recruitment. Abaloparatide TFA enhances bone formation and cortical structure in mice. Abaloparatide TFA has the potential for the research of osteoporosis .
|
-
-
- HY-110218
-
CW 008
1 Publications Verification
|
PKA
Epigenetic Reader Domain
|
Others
|
|
CW 008, a derivative of pyrazole-pyridine, is a CREB or PKA pathway agonist. CW 008 also is a stem cell differentiating agent. CW 008 stimulates osteoblast differentiation of human MSCs and increases bone formation in ovariectomized mice. CW008 promotes osteogenesis by activating cAMP/PKA/CREB signaling pathway and inhibiting leptin secretion .
|
-
-
- HY-12398
-
|
|
VD/VDR
|
Metabolic Disease
Inflammation/Immunology
|
|
TEI-9647, a Vitamin D3 Lactone analogue, is a potent and specific vitamin D receptor (VDR) antagonist. TEI-9647 inhibits VDR/VDRE-mediated genomic actions of 1α,25(OH)2D3. TEI-9647 inhibits bone resorption and HL-60 cell differentiation induced by of 1α,25(OH)2D3. TEI-9647 has the potential for suppressing the excessive bone resorption and osteoclast formation in Paget's disease .
|
-
-
- HY-16268
-
|
KGN
|
TGF-beta/Smad
|
Inflammation/Immunology
|
|
Kartogenin (KGN) is an inducer of chondrogenic tissue formation (EC50: 100 nM). Kartogenin induces chondrogenesis by binding to fibrin A, disrupting its interaction with the transcription factor core binding factor beta subunit (CBFβ), and by modulating the CBFβ-RUNX1 transcriptional program. Kartogenin also promotes tendon-bone junction (TBJ) wound healing by stimulating collagen synthesis. Kartogenin is widely used in cell-free therapy in the field of regeneration for cartilage regeneration and protection, tendon-bone healing, wound healing and limb development. Kartogenin promotes cartilage repair, coordinates limb development, and is also used in osteoarthritis (OA) research .
|
-
-
- HY-16268A
-
|
KGN sodium
|
TGF-beta/Smad
|
Inflammation/Immunology
|
|
Kartogenin (KGN) sodium is an inducer of chondrogenic tissue formation (EC50: 100 nM). Kartogenin sodium induces chondrogenesis by binding to fibrin A, disrupting its interaction with the transcription factor core binding factor beta subunit (CBFβ), and by modulating the CBFβ-RUNX1 transcriptional program. Kartogenin sodium also promotes tendon-bone junction (TBJ) wound healing by stimulating collagen synthesis. Kartogenin sodium is widely used in cell-free therapy in the field of regeneration for cartilage regeneration and protection, tendon-bone healing, wound healing and limb development. Kartogenin sodium promotes cartilage repair, coordinates limb development, and is also used in osteoarthritis (OA) research .
|
-
-
- HY-130237
-
|
|
Reactive Oxygen Species
|
Metabolic Disease
Cancer
|
|
Cinnamtannin B-1 is a proanthocyanidin with multiple biological functions, including antioxidant effects and inhibiting the production of reactive oxygen species (ROS). Cinnamtannin B-1 inhibits RANKL-induced osteoclastogenesis and prevents ovariectomy-induced osteoporosis in vivo. Cinnamtannin B-1 can be used for the research osteoporosis and colon cancers .
|
-
-
- HY-110280
-
|
|
HDAC
Apoptosis
|
Cancer
|
|
MC1742 is a potent HDAC inhibitor, with IC50s of 0.1 μM, 0.11 μM, 0.02 μM, 0.007 μM, 0.61 μM, 0.04 μM and 0.1 μM for HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, HDAC10 and HDAC11, respectively. MC1742 can increase acetyl-H3 and acetyl-tubulin levels and inhibits cancer stem cells growth. MC1742 can induce growth arrest, apoptosis, and differentiation in sarcoma CSC .
|
-
-
- HY-130237R
-
|
|
Reactive Oxygen Species
|
Metabolic Disease
Cancer
|
|
Cinnamtannin B-1 (Standard) is the analytical standard of Cinnamtannin B-1. This product is intended for research and analytical applications. Cinnamtannin B-1 is a proanthocyanidin with multiple biological functions, including antioxidant effects and inhibiting the production of reactive oxygen species (ROS). Cinnamtannin B-1 inhibits RANKL-induced osteoclastogenesis and prevents ovariectomy-induced osteoporosis in vivo. Cinnamtannin B-1 can be used for the research osteoporosis and colon cancers .
|
-
-
- HY-163707
-
|
|
Apoptosis
|
Cancer
|
|
UR778Br targets the GTPase-activating protein-related domain (GRD domain) of IQGAP1 proteins. UR778Br inhibits the proliferation of human acute myeloid leukemia (AML), arrests the cell cycle at the G2/M phase, and induces apoptosis. UR778Br inhibits colony formation of primary and AML cells, without significant impacts on normal bone marrow cells .
|
-
-
- HY-117182
-
|
|
Apoptosis
VD/VDR
RAR/RXR
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
LG190178 is a non-steroidal vitamin D receptor (VDR) ligand that can induce the formation of heterodimer complexes between VDR and retinoid X receptor (RXR), stabilizing the agonistic conformation of the VDR ligand-binding domain and promoting its interaction with co-activators. LG190178 has functions in regulating calcium homeostasis, bone mineralization, as well as cell proliferation, differentiation, and apoptosis, making it useful for research in psoriasis, osteoporosis, and cancer .
|
-
- HY-N6973
-
Boldine
1 Publications Verification
|
RANKL/RANK
Apoptosis
|
Inflammation/Immunology
|
|
Boldine is an apomorphine isoquinoline alkaloid extracted from the root of the pheasant pepper (Litsea cubeba). Boldine is an oral effective antioxidant, anti-inflammatory, antitumor agent, and can inhibit osteoclast formation. Boldine induces apoptosis of human bladder cancer cells by regulating ERK, AKT and GSK-3β. Boldine ameliorates bone destruction by down-regulating the OPG/RANKL/RANK signaling pathway. It can be used in rheumatoid arthritis research .
|
-
- HY-168090
-
|
|
p38 MAPK
NF-κB
RANKL/RANK
|
Endocrinology
|
|
Anti-osteoporosis agent-11 (compound 3k) is an anti-osteoporosis compound targeting osteoclasts. Anti-osteoporosis agent-11 has the most significant inhibitory effect on osteoclast differentiation, with an IC50 value of 0.36 μM. In addition, Anti-osteoporosis agent-11 inhibits osteoclast formation, bone resorption, and the expression of osteoclast-specific genes by blocking rankl-induced mitogen-activated protein kinase (MAPK) and NF-κB signaling pathways .
|
-
- HY-121282B
-
|
Pecazine acetate
|
Apoptosis
MALT1
|
Others
|
|
Mepazine acetate (Pecazine acetate) is a drug that has the activity to inhibit the protease activity of MALT1. Mepazine acetate is often used to study the role of MALT1 in biology. Treatment of mouse bone marrow precursor cells with mepazine acetate strongly inhibited RANK ligand (RANKL)-induced osteoclast formation. Mepazine acetate also inhibited the expression of multiple osteoclast markers such as TRAP, feline hepsin K, and calcitonin. The protective effect of mepazine acetate was not affected by MALT1 deficiency. The mechanism of action of mepazine acetate may involve MALT1-independent mechanisms, and this aspect needs to be considered in future studies .
|
-
- HY-N2037A
-
|
Norcoclaurine hydrochloride
|
MAP3K
MDM-2/p53
ROS Kinase
Apoptosis
|
Infection
Cardiovascular Disease
Endocrinology
Cancer
|
|
Higenamine hydrochloride is a selective LSD1 inhibitor (IC50=1.47 μM) that can be isolated from aconite. Higenamine hydrochloride has anti-inflammatory and antibacterial activity. Higenamine (Norcoclaurine) can attenuate IL-1β-induced Apoptosis through ROS-mediated PI3K/Akt signaling pathway. Higenamine hydrochloride protects brain cells from oxygen deprivation. Higenamine can promote bone formation in osteoporosis through the SMAD2/3 pathway. Higenamine hydrochloride can be used to study cancer, inflammation, cardiorenal syndrome and other diseases .
|
-
- HY-N2037AR
-
|
|
MAP3K
MDM-2/p53
ROS Kinase
Apoptosis
|
Infection
Cardiovascular Disease
Endocrinology
Cancer
|
|
Higenamine (hydrochloride) (Standard) is the analytical standard of Higenamine (hydrochloride). This product is intended for research and analytical applications. Higenamine hydrochloride is a selective LSD1 inhibitor (IC50=1.47 μM) that can be isolated from aconite. Higenamine hydrochloride has anti-inflammatory and antibacterial activity. Higenamine (Norcoclaurine) can attenuate IL-1β-induced Apoptosis through ROS-mediated PI3K/Akt signaling pathway. Higenamine hydrochloride protects brain cells from oxygen deprivation. Higenamine can promote bone formation in osteoporosis through the SMAD2/3 pathway. Higenamine hydrochloride can be used to study cancer, inflammation, cardiorenal syndrome and other diseases .
|
-
- HY-N2037
-
|
Norcoclaurine; Demethyl-Coclaurine
|
MAP3K
MDM-2/p53
Adrenergic Receptor
ROS Kinase
Apoptosis
|
Cardiovascular Disease
Endocrinology
|
|
Higenamine (Norcoclaurine), a β2-AR agonist with antioxidant capability, is a key component of the Chinese herb aconite root that prescribes for treating symptoms of heart failure in the oriental Asian countries. Higenamine is also a α1-adrenergic receptor antagonist with hypotensive effect. is a selective LSD1 inhibitor (IC50=1.47 μM) that can be isolated from aconite. Higenamine hydrochloride has anti-inflammatory and antibacterial activity. Higenamine protects myocyte Apoptosis and ischemia/reperfusion (I/R) injury through selective activation of beta2-adrenergic receptor (β2-AR). Higenamine also reduces I/R-induced myocardial infarction in mice. Higenamine can attenuate IL-1β-induced Apoptosis through ROS-mediated PI3K/Akt signaling pathway. Higenamine protects brain cells from oxygen deprivation. Higenamine can promote bone formation in osteoporosis through the SMAD2/3 pathway. Higenamine can be used to study cancer, inflammation, cardiorenal syndrome and other diseases .
|
-
-
-
HY-L131
-
|
|
483 compounds
|
|
Ossification is a tightly regulated process, performed by specialized cells called osteoblasts. Dysregulation of this process may cause inadequate or excessive mineralization of bones or ectopic calcification, all of which have grave consequences for human health.
Osteoblasts play important roles in the process of osteogenesis and prevention of osteonecrosis. Osteoblast formation and bone formation are regulated by hormones, growth factors, cytokines, etc.
MCE offers a unique collection of 483 bone formation compounds with identified and potential inducing osteogenesis activity. MCE bone formation compound library is a useful tool for the study of bone disease drugs and pharmacology.
|
| Cat. No. |
Product Name |
Type |
-
- HY-B2200
-
|
Tricalcium dicitrate tetrahydrate, 99%
|
Buffer Reagents
|
|
Calcium citrate tetrahydrate, 99% exhibits the ability to release more calcium ions in a short time therefore allowing a high activity, and a high concentration of calcium ions that can stimulate bone formation .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P0322
-
|
EMD 56574
|
Integrin
|
Cardiovascular Disease
Metabolic Disease
|
|
GRGDSPK (EMD 56574) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK (EMD 56574) is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK is used to study the role of integrins in bone formation and resorption .
|
-
- HY-P0090
-
|
Salmon calcitonin
|
CGRP Receptor
|
Cancer
|
|
Calcitonin salmon, a calcium regulating hormone, is a dual-action amylin and calcitonin receptor agonist, could stimulate bone formation and inhibit bone resorption.
|
-
- HY-P4823
-
|
|
Thyroid Hormone Receptor
|
Metabolic Disease
|
|
pTH (1-37) (human) is a fragment of parathyroid hormone (PTH). pTH (1-37) (human) induces the cAMP formation and increases alkaline phosphatase activity. pTH (1-37) (human) increases growth, bone calcium content, and bone mineral density (BMD) in uremic animals. pTH (1-37) (human) has the potential for the research of osteoporosis .
|
-
- HY-P4588
-
|
|
Peptides
|
Metabolic Disease
|
|
(Glu17,21,24)-Osteocalcin (1-49) (human) is a bone-specific protein involved in bone formation and glucose metabolism .
|
-
- HY-P5929
-
|
|
Integrin
FAK
|
Inflammation/Immunology
|
|
VnP-16 can promote bone formation by accelerating osteoblast differentiation and activity through direct interaction with β1 integrin followed by FAK activation .
|
-
- HY-P0322A
-
|
EMD 56574 TFA
|
Integrin
|
Cardiovascular Disease
Metabolic Disease
|
|
GRGDSPK TFA (EMD 56574 TFA) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK TFA is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK TFA is used to study the role of integrins in bone formation and resorption .
|
-
- HY-P0090A
-
|
Salmon calcitonin acetate
|
CGRP Receptor
|
Cancer
|
|
Calcitonin (salmon) (acetate) is a dual-action amylin and calcitonin receptor agonist, can stimulate bone formation and inhibit bone resorption .The acetate form can affect the absorption and efficacy of hormones .
|
-
- HY-P4835
-
|
|
Peptides
|
Others
|
|
pTH (2-34) (human) (80 μg/kg) slightly increases serum osteocalcin levels and alkaline phosphatase activity of bone extract (markers of bone formation) in mice. pTH (2-34) is not as effective as pTH (1-34) .
|
-
- HY-P4849
-
|
|
Peptides
|
Others
|
|
pTH-Related Protein (1-37) (human, mouse, rat), the peptide analogue of pTH-Related Protein (pTHrP). pTHrP refers to parathyroid-hormone-related protein, involved in physiological regulation of bone formation .
|
-
- HY-P4817
-
|
|
Thyroid Hormone Receptor
|
Metabolic Disease
|
|
Human PTH-(1-31) is the 1-31 fragment of human PTH. Human PTH-(1-31) stimulates the release of cAMP and also is a weaker stimulator of the 25-hydroxyvitamin D-1α-hydroxylase. Human PTH-(1-31) induces bone formation without inducing bone resorption. Human PTH-(1-31) has the potential for the research of osteoporosis .
|
-
- HY-108742
-
|
BA 058; BIM 44058
|
Thyroid Hormone Receptor
Arrestin
|
Metabolic Disease
|
|
Abaloparatide (BA 058) is a parathyroid hormone receptor 1 (PTHR1) analog. Abaloparatide also is a selective PTHR1 activator. Abaloparatide enhances Gs/cAMP signaling and β-arrestin recruitment. Abaloparatide enhances bone formation and cortical structure in mice. Abaloparatide has the potential for the research of osteoporosis .
|
-
- HY-108742A
-
|
BA 058 TFA; BIM 44058 TFA
|
Thyroid Hormone Receptor
Arrestin
|
Metabolic Disease
Endocrinology
|
|
Abaloparatide TFA (BA 058 TFA) is a parathyroid hormone receptor 1 (PTHR1) analogue. Abaloparatide TFA also is a selective PTHR1 activator. Abaloparatide TFA enhances Gs/cAMP signaling and β-arrestin recruitment. Abaloparatide TFA enhances bone formation and cortical structure in mice. Abaloparatide TFA has the potential for the research of osteoporosis .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P9982
-
|
|
Inhibitory Antibodies
|
Endocrinology
Cancer
|
|
Romosozumab is a humanized monoclonal anti-sclerostin antibody, it promotes bone formation and inhibits bone resorption by inhibiting sclerostin. Romosozumab can be used for the research of osteoporosis .
|
-
- HY-P99186
-
|
|
Inhibitory Antibodies
|
Others
|
|
Blosozumab (LY2541546) is an anti-Human sclerostin (SOST) antibody inhibitor. Blosozumab stimulates bone formation and reduces bone resorption. Blosozumab can be used in the research of Osteoporosis .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
